National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Filgotinib (Jyseleca®). HTA ID: 20047

Filgotinib is indicated as monotherapy or in combination with methotrexate for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs.

 

NCPE Assessment Process Complete
Rapid review commissioned 13/10/2020
Rapid review completed 16/11/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of filgotinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.